Related Experiment Videos
Systemic therapy for advanced or recurrent endometrial carcinoma
1Section of Hematology/Oncology, University of Chicago Medical Center, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637-1470, USA.
Current Oncology Reports
|December 21, 2000
Summary
Treatment for metastatic or recurrent endometrial cancer has poor prognosis. Chemotherapy and hormone therapy show some benefit, with new targeted treatments like anti-HER2/neu antibodies under investigation for improved outcomes.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Cancer Therapeutics
Background:
- Metastatic or recurrent endometrial cancer carries a poor prognosis.
- Current treatment options offer limited long-term survival benefits.
- Identifying predictive markers for therapy response is crucial.
Purpose of the Study:
- To review current treatment strategies for advanced endometrial cancer.
- To evaluate the efficacy of chemotherapy and hormone therapy.
- To explore novel therapeutic approaches, including targeted therapies.
Main Methods:
- Review of existing literature on endometrial cancer treatment.
- Analysis of response rates for various chemotherapy regimens (anthracyclines, platinum, paclitaxel).
- Discussion of hormone therapy selection based on receptor status and emerging targeted agents.
Main Results:
- Standard chemotherapy agents achieve response rates exceeding 20%.
- Combination chemotherapy increases response rates but not survival, with significant toxicity.
- Hormone therapy is effective in a subset of patients identified by receptor status.
Conclusions:
- While chemotherapy offers response, survival benefits are limited.
- Hormone therapy and targeted agents like anti-HER2/neu antibodies represent promising avenues for specific patient subsets.
- Ongoing research into new drugs and combinations is essential for improving outcomes in recurrent endometrial cancer.